Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.
Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?